


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-0.76%
-0.38%
+1.44%
+1.76%
+5.21%
HCM
HUTCHMED (China) Limited
$15.30
Strengths

Earnings are forecast to grow
HCM Price Performance
$13.26 (+15.38%)
$15.2 (+0.66%)
$16.11 (-5.03%)
$13.52 (+13.17%)
HCM has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Low volume

HCM overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
HCM Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
HCM Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
AZN
96.34
+1.94%
VSTM
6.79
-5.69%
MRK
111.01
+2.54%
MBRX
4.14
-3.50%
LLY
1073.29
-0.36%
What is HCM current stock price?
What are HCM stock strengths?
What is HCM Risk Level?
What is HCM market cap and volume?
What is HCM current Stock IQ?
Should I buy HCM stock right now?
Is HCM a Strong Buy right now?
What does a 'Strong Buy' rating mean for HCM?
What does a 'Strong Sell' rating mean for HCM?
What factors influence HCM's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-0.76%
-0.38%
+1.44%
+1.76%
+5.21%
HCM
HUTCHMED (China) Limited
Current Price
$15.30
HCM Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow
Linked to HCM
AZN
96.34
+1.94%
VSTM
6.79
-5.69%
MRK
111.01
+2.54%
MBRX
4.14
-3.50%
LLY
1073.29
-0.36%

HCM Price Performance
$13.26 (+15.38%)
$15.2 (+0.66%)
$16.11 (-5.03%)
$13.52 (+13.17%)
HCM Analysts Opinion
HCM Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
HCM Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
HCM Street Sentiment is extremely bullish and have positive views on the near-term outlook
HCM has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Low volume

Average key support and resistance price levels
HCM Latest Analysis
Wall Street Analysts Predict a 55.93% Upside in HUTCHMED (HCM): Heres What You Should Know. The consensus price target hints at a 55.9% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hardly effective an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wed Jan 7, 2026
HUTCHMEDs Sovleplenib Reaches Phase III Goal In Warm Autoimmune Hemolytic Anemia Trial In China . (RTTNews) - HUTCHMED (China) Limited (HCM HCM.L 0013.HK) announced that the Phase III registration portion of the ESLIM-02 clinical trial evaluating sovleplenib a novel spleen tyrosine kinase (Syk) inhibitor in adult patients with warm antibody autoimmune hemolytic anemia (wA
Wed Jan 7, 2026
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma. — NDA supported by results from a Phase II registration trial in China —
Mon Dec 29, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.